(SRPT) Sarepta Therapeutics, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(SRPT) Sarepta Therapeutics, Inc. Complete Analysis Pack
Unlock Strategic Clarity
This Sarepta Therapeutics, Inc. BCG Matrix is a company-specific strategy tool used to assess its products or business units across the Stars, Cash Cows, Question Marks, and Dogs quadrants. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report instantly.
Stars
ELEVIDYS SRP-9001 1 approved DMD gene therapy
ELEVIDYS is Sarepta Therapeutics, Inc.'s main growth engine at end-2025: it is still the only FDA-approved gene therapy in the U.S. for Duchenne muscular dystrophy. Demand is strong, but the case is not clean, since safety events and label changes can hit uptake fast. That makes it a Star with high growth and high risk.
DMD gene-therapy market 1 first-mover position
Sarepta Therapeutics, Inc. was first to commercialize an approved DMD gene therapy, giving it a clear lead in this Star market. DMD affects about 1 in 3,500 male births, so the patient pool is still large as diagnosis and access improve. High unmet need should keep uptake growing, even as competition builds.
Roche ex-U.S. ELEVIDYS rights 1 global expansion option
Roche gives Sarepta a low-capex path to expand ELEVIDYS outside the U.S., so it can reach the ~300,000 global Duchenne muscular dystrophy patient pool without building every market alone. Ex-U.S. uptake is still early, so the revenue base is small today. If reimbursement and launch execution improve, this looks like a Star: high growth, with room to scale fast.
AAV manufacturing scale-up 2025 capacity build
AAV manufacturing is a key support for Sarepta Therapeutics, Inc.'s ELEVIDYS push: gene therapy needs clean, batch-specific production, and each extra slot can lift output over time. In 2025, more in-house capacity helps Sarepta scale a product that generated $384.8 million in net product revenue in Q1 2025.
This makes the build-out a Star support asset, not a standalone driver. More capacity can reduce supply bottlenecks and support higher ELEVIDYS volumes as demand grows.
- Specialized AAV lines protect gene therapy supply.
- Capacity adds room for ELEVIDYS volume growth.
- It supports a high-growth Star franchise.
Duchenne commercial brand 4 product franchise momentum
Sarepta Therapeutics, Inc. built a four-product Duchenne muscular dystrophy franchise around Exondys 51, Vyondys 53, Amondys 45, and Elevidys, giving it the widest commercial footprint in DMD. Demand stays durable because Duchenne is a rare, progressive disease with long treatment duration, so each new patient adds to a sticky base. That scale helps Sarepta compound faster than smaller peers in the same rare-disease niche.
- Four branded DMD therapies drive reach
- Rare-disease demand stays persistent
- Scale supports faster franchise compounding
ELEVIDYS Keeps Sarepta in Star Territory
ELEVIDYS keeps Sarepta Therapeutics, Inc. in Star territory: it is the only FDA-approved gene therapy for Duchenne muscular dystrophy, and Q1 2025 net product revenue reached $384.8 million. Demand is rising, but safety and label risk can slow adoption.
With a rare-disease base of about 1 in 3,500 male births and Roche-led ex-U.S. reach, the franchise still has room to scale.
| Star metric | Data |
|---|---|
| ELEVIDYS status | Only FDA-approved DMD gene therapy |
| Q1 2025 revenue | $384.8 million |
| DMD incidence | 1 in 3,500 male births |
What is included in the product
Detailed Word Document
Sarepta’s BCG Matrix maps its gene-therapy and RNA drugs by growth and share, flagging where to invest, hold, or cut.
Editable Excel File
Clean, quadrant-based BCG view of Sarepta Therapeutics to quickly spot growth, cash, and divestment priorities.
Reference Sources
Provides a clear source trail for Sarepta Therapeutics, helping users verify claims quickly and make more confident decisions.
Cash Cows
EXONDYS 51 2016 exon 51 PMO
EXONDYS 51, launched in 2016, is a mature Duchenne muscular dystrophy therapy with strong prescriber familiarity and a narrow exon 51 patient base. It remains a Cash Cow because demand is recurring and brand recognition is high, even as growth has slowed. Sarepta's DMD franchise still generated over $1 billion in annual product sales recently, supporting steady cash flow.
VYONDYS 53 2019 exon 53 PMO
VYONDYS 53, approved in 2019 for Duchenne patients amenable to exon 53 skipping, fits a Cash Cow profile because it serves a niche that is relatively stable and hard to disrupt. Exon 53 mutations account for about 8% of Duchenne cases, so the addressable pool is small but durable. With an entrenched base and low incremental launch spend, it keeps generating cash for Sarepta Therapeutics, Inc.
AMONDYS 45 2021 exon 45 PMO
AMONDYS 45 extends Sarepta Therapeutics, Inc.'s exon-skipping franchise into the exon 45 segment, but the addressable pool is small: exon 45 skipping fits only about 8% of Duchenne muscular dystrophy patients. It is approved and commercial, yet DMD itself affects roughly 1 in 3,500 to 5,000 male births, so this is a narrow, mature niche. That profile makes AMONDYS 45 more of a harvest asset than a growth driver.
DMD exon-skipping franchise 3 approved PMOs
EXONDYS 51, VYONDYS 53, and AMONDYS 45 give Sarepta Therapeutics, Inc. a durable 3-product PMO base in Duchenne muscular dystrophy. The franchise has long physician familiarity and established payer coverage, so it keeps cash flow coming while newer gene and RNA programs are scaled. In FY2025, that kind of repeat revenue still matters more than launch-stage hype.
- 3 approved PMOs support steady sales
- Physician awareness is already built
- Payer pathways are already in place
- Cash can fund newer programs
Neuromuscular maintenance sales 2025 recurring revenue base
Sarepta Therapeutics, Inc.’s legacy Duchenne franchise, led by EXONDYS 51, VYONDYS 53, and AMONDYS 45, still earns repeat prescriptions and follow-on demand. These products are commercially established and sit in a low-growth category, which fits the Cash Cows profile. In 2025, that base helped support steady revenue while the newer gene therapy line drove growth.
- Repeat use, not rapid expansion
- Established market, strong brand recall
- Cash generation from mature therapies
Mature Duchenne Drugs Deliver Steady Cash Flow
EXONDYS 51, VYONDYS 53, and AMONDYS 45 are mature Duchenne assets with repeat use, stable payer access, and low launch spend, so they fit Cash Cows. Exon 45 and exon 53 each cover about 8% of Duchenne cases, which keeps the pool small but durable. In FY2025, this base still helped fund newer programs and steady cash flow.
| Asset | Cash Cow cue | Data point |
|---|---|---|
| EXONDYS 51 | Established brand | Launched 2016 |
| VYONDYS 53 | Niche demand | About 8% exon 53 |
| AMONDYS 45 | Harvest asset | About 8% exon 45 |
Preview the Actual Deliverable
Sarepta Therapeutics, Inc. Reference Sources
You’re previewing the exact Sarepta Therapeutics, Inc. BCG Matrix document you’ll receive after purchase. The full report is delivered without watermarks, demo pages, or hidden sections. What you see here is the same professionally formatted file ready for immediate use.
Dogs
Lysogene collaboration 1 non-commercial alliance
Lysogene collaboration is a non-commercial research alliance, so it has 0 product sales and 0% market share today. Its BCG Matrix fit is Dog because value depends only on future clinical and FDA success, not current cash flow. For Sarepta Therapeutics, Inc., this is an option on pipeline upside, not a revenue driver.
Nationwide Children's Hospital partnership 1 early-stage tie-up
Nationwide Children"s Hospital partnership is an early-stage research tie-up, not a commercial brand, so it adds little or no current revenue to Sarepta Therapeutics, Inc. In BCG terms, that keeps it in Dogs: low market share, low near-term return, and high dependence on future trial outcomes. It is a strategic option, not a cash engine.
Duke University collaboration 1 academic program link
Duke University collaboration is a small academic link, not a cash-flow engine, and it has no branded product tied to it today. In Sarepta Therapeutics, Inc. BCG terms, it fits a Dog because it is non-core and does not yet convert research into near-term sales. It can still seed future assets, but its current financial weight is close to zero.
Genethon collaboration 1 pre-commercial genetics link
Genethon collaboration is scientifically useful for Sarepta Therapeutics, Inc., but it is still a pre-commercial genetics link, so there is no marketed franchise and no direct sales share today. The economics stay milestone-based, which keeps near-term cash contribution limited and makes it more of a pipeline option than a BCG Cash Cow. In BCG terms, this fits a Question Mark, not a Star or Dog.
- No marketed revenue today
- Value is scientific, not commercial
- Cash flows depend on milestones
- Near-term economics stay limited
StrideBio collaboration 1 exploratory gene-therapy tie-up
StrideBio collaboration 1 is an exploratory gene-therapy tie-up, so it is an option on future science, not a current product. Sarepta Therapeutics, Inc. has not disclosed material revenue from it, so today it adds little or no cash flow and fits the BCG dog profile unless it scales into a larger program.
In 2025, Sarepta Therapeutics, Inc. still had most revenue tied to approved Duchenne products, not this collaboration, so the tie-up remains low-share and low-monetization.
- Early-stage, not commercial
- Little or no current revenue
- Dog only if it stays small
Sarepta Collaborations: Pre-Commercial Dogs With Little 2025 Revenue
These Sarepta Therapeutics, Inc. collaborations are Dogs because they are still pre-commercial and bring little or no 2025 revenue. None has a marketed product or meaningful market share, so current cash flow is near zero. Their value is scientific optionality, not sales. If any scales into a bigger program, the BCG label can change.
| Program | 2025 rev | BCG |
|---|---|---|
| Academic/biotech ties | 0 | Dog |
Question Marks
SRP-5051 51 exon next-gen PPMO
SRP-5051 targets the same Duchenne exon 51 patient pool as EXONDYS 51, and about 13% of Duchenne cases are exon 51-amenable. The market is attractive, but share is not locked in; with EXONDYS 51 already a $200M+ franchise, SRP-5051 must prove better data and adoption to move from Question Mark to Star.
SRP-9003 LGMD2E gene therapy
SRP-9003 LGMD2E is a question mark in Sarepta Therapeutics, Inc.’s BCG Matrix: it is a high-upside gene-therapy bet in a rare muscle disease, but it has no commercial share yet. The addressable LGMD market is still niche, with patient counts in the low thousands and no approved SRP-9003 revenue. Value depends on clear clinical data and U.S. FDA approval, or it stays a cash-consuming R&D asset.
Non-ambulatory DMD ELEVIDYS expansion 2025
ELEVIDYS is a Question Mark for Sarepta Therapeutics, Inc. because the non-ambulatory Duchenne muscular dystrophy pool is much larger than the original launch base, but uptake still depends on access and payer coverage. The FDA expanded the label in June 2024 to ages 4+ regardless of ambulation, yet real share remains limited while the company grows from a 1-shot gene therapy base. Safety and post-marketing outcomes will decide scale.
Ex-U.S. ELEVIDYS rollout 2025
Ex-U.S. ELEVIDYS rollout in 2025 is still early, so Sarepta Therapeutics, Inc. has only a small installed base outside the U.S. The upside is real: Duchenne muscular dystrophy affects about 1 in 3,500 to 5,000 male births worldwide, and Roche is still building access and reimbursement. That makes this a classic Question Mark in the BCG Matrix.
Early share outside the U.S.
Large and growing addressable market
High upside, but adoption risk remains
Next-gen LGMD portfolio 2025 pipeline
Sarepta Therapeutics, Inc. next-gen LGMD gene-therapy assets, including SRP-9003, SRP-9004, and SRP-9005, are still Question Marks: they target rare muscle diseases with no approved commercial traction yet. As of 2025, these programs remain clinical-stage and investment-heavy, while the LGMD market is still early but scientifically attractive.
- Clinical-stage only, no sales yet
- High unmet need, but high trial risk
- Needs capital before scale-up
Sarepta’s Question Marks: Pipeline Bets With Big Upside, Little Proof
Sarepta Therapeutics, Inc. Question Marks are the pipeline bets with big disease pools but little or no proven share yet. SRP-5051, SRP-9003, SRP-9004, and SRP-9005 still need clear clinical wins, while ELEVIDYS outside the U.S. is early and payer-led adoption remains the key swing factor.
| Asset | Status | Key data |
|---|---|---|
| SRP-5051 | Question Mark | ~13% exon 51 DMD |
| SRP-9003 | Question Mark | LGMD2E, no sales |
| ELEVIDYS ex-U.S. | Question Mark | 2025 rollout early |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.